These innovative agents represent a significant leap in the therapy of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://sahiljhqu918848.liberty-blog.com/39362491/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide